Applied DNA Sciences and Smiths Detection Sign MoU to Provide Forensic Testing for SigNature™ DNA
News May 06, 2008
Under the terms of the MOU, Smiths will provide APDN with exclusive use of the Bio-seeq™PLUS platform, centered upon a portable, DNA-verifying device for authentication, anti-counterfeiting and anti-diversion. When used in combination with APDN’s SigNature™ DNA markers, the Bio-seeq™PLUS will provide forensic authentication in the field.
The BioSeeq™ platform was originally developed by Smiths for use by first responders to test for biological agents, where reliability and precision are essential. The Bio-seeq™PLUS is a new version of the system which uses LATE PCR (Linear After The Exponential PCR) a technique for detecting and analyzing small amounts of nucleic acid.
Smiths hold an exclusive license to LATE PCR from Brandeis University. Bio-seeq™PLUS uses a system of disposable reagent cartridges, which allow use in the field with little technical training. The device is a handheld, fully field-portable PCR identifier that is designed to provide results in as little as 20 minutes depending on the type of assay developed. It supports up to 6 independent simultaneous assays.
Dr. James Hayward, APDN President & CEO stated: “The Bio-seeq™PLUS rounds out our three-pronged offering for authenticating originality: nearly instantaneous optical screening, backed up by in-field forensic marker verification, and ultimately supported when required for legal reasons, by in-lab DNA sequencing. We are committed 100% to ensuring that products and documents that have our unique SigNature™ DNA markers can be quickly and forensically authenticated anywhere in the world. More than a deterrent, our SigNature™ marks will catch counterfeiters and enable effective prosecution by manufacturers and Intellectual Property owners.”
Scientists from the UNC School of Medicine discovered that the anti-inflammatory protein NLRP12 normally helps protect mice against obesity and insulin resistance when they are fed a high-fat diet. The researchers also reported that the NLRP12 gene is underactive in people who are obese, making it a potential therapeutic target for treating obesity and diabetes.READ MORE